88 related articles for article (PubMed ID: 8399329)
1. Synthesis and use of novel fluorescent glycosphingolipids for estimating beta-glucosidase activity in vitro in the absence of detergents and subtyping Gaucher disease variants following administration into intact cells.
Agmon V; Cherbu S; Dagan A; Grace M; Grabowski GA; Gatt S
Biochim Biophys Acta; 1993 Sep; 1170(1):72-9. PubMed ID: 8399329
[TBL] [Abstract][Full Text] [Related]
2. Intracellular degradation of fluorescent glycolipids by lysosomal enzymes and their activators.
Madar-Shapiro L; Pasmanik-Chor M; Dinur T; Dagan A; Gatt S; Horowitz M
J Inherit Metab Dis; 1999 Jun; 22(5):623-37. PubMed ID: 10399095
[TBL] [Abstract][Full Text] [Related]
3. The fate of glucosylceramide (glucocerebroside) in genetically impaired (lysosomal beta-glucosidase deficient) Gaucher disease diploid human fibroblasts.
Saito M; Rosenberg A
J Biol Chem; 1985 Feb; 260(4):2295-300. PubMed ID: 3919000
[TBL] [Abstract][Full Text] [Related]
4. Use of activators and inhibitors to define the properties of the active site of normal and Gaucher disease lysosomal beta-glucosidase.
Gatt S; Dinur T; Osiecki K; Desnick RJ; Grabowski GA
Enzyme; 1985; 33(2):109-19. PubMed ID: 3924590
[TBL] [Abstract][Full Text] [Related]
5. Acid beta-glucosidase: enzymology and molecular biology of Gaucher disease.
Grabowski GA; Gatt S; Horowitz M
Crit Rev Biochem Mol Biol; 1990; 25(6):385-414. PubMed ID: 2127241
[TBL] [Abstract][Full Text] [Related]
6. beta-Glucosidase isoenzymes in Epstein-Barr virus-transformed lymphoid cell lines from normal subjects and patients with type 1 Gaucher disease.
Maret A; Salvayre R; Samadi M; Douste-Blazy L
Enzyme; 1987; 37(4):208-17. PubMed ID: 3038513
[TBL] [Abstract][Full Text] [Related]
7. Analysis of glucocerebrosidase activity using N-(1-[14C]hexanoyl)-D-erythroglucosylsphingosine demonstrates a correlation between levels of residual enzyme activity and the type of Gaucher disease.
Meivar-Levy I; Horowitz M; Futerman AH
Biochem J; 1994 Oct; 303 ( Pt 2)(Pt 2):377-82. PubMed ID: 7980395
[TBL] [Abstract][Full Text] [Related]
8. Genetic heterogeneity in Gaucher disease: physicokinetic and immunologic studies of the residual enzyme in cultured fibroblasts from non-neuronopathic and neuronopathic patients.
Grabowski GA; Goldblatt J; Dinur T; Kruse J; Svennerholm L; Gatt S; Desnick RJ
Am J Med Genet; 1985 Jul; 21(3):529-49. PubMed ID: 3927728
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of a fluorescent derivative of glucosyl ceramide for the sensitive determination of glucocerebrosidase activity.
Dinur T; Grabowski GA; Desnick RJ; Gatt S
Anal Biochem; 1984 Jan; 136(1):223-34. PubMed ID: 6424502
[TBL] [Abstract][Full Text] [Related]
10. An in situ study of beta-glucosidase activity in normal and Gaucher fibroblasts with fluorogenic probes.
Kohen E; Kohen C; Hirschberg JG; Santus R; Grabowski G; Mangel W; Gatt S; Prince J
Cell Biochem Funct; 1993 Sep; 11(3):167-77. PubMed ID: 8403230
[TBL] [Abstract][Full Text] [Related]
11. Identification of a feedback loop involving β-glucosidase 2 and its product sphingosine sheds light on the molecular mechanisms in Gaucher disease.
Schonauer S; Körschen HG; Penno A; Rennhack A; Breiden B; Sandhoff K; Gutbrod K; Dörmann P; Raju DN; Haberkant P; Gerl MJ; Brügger B; Zigdon H; Vardi A; Futerman AH; Thiele C; Wachten D
J Biol Chem; 2017 Apr; 292(15):6177-6189. PubMed ID: 28258214
[TBL] [Abstract][Full Text] [Related]
12. Assay of the beta-glucosidase activity with natural labelled and artificial substrates in cultivated skin fibroblasts from homozygotes and heterozygotes with the Norrbottnian type of Gaucher disease.
Håkansson G; Dreborg S; Lindsten J; Svennerholm L
Clin Genet; 1980 Oct; 18(4):268-73. PubMed ID: 6777099
[TBL] [Abstract][Full Text] [Related]
13. In vitro detergent activation of lysosomal acid beta-glucosidase in the spleen of normal and type 1 Gaucher patients is not accompanied by change in aggregation state.
Maret A; Potier M; Salvayre R; Troly M; Beauregard G; Douste-Blazy L
Biochim Biophys Acta; 1989 Jul; 996(3):254-6. PubMed ID: 2502183
[TBL] [Abstract][Full Text] [Related]
14. Genetic heterogeneity in type I Gaucher disease.
Devine EA; Beighton P; Petersen EM; Desnick RJ
Prog Clin Biol Res; 1982; 95():495-510. PubMed ID: 6812084
[TBL] [Abstract][Full Text] [Related]
15. Biochemical and molecular characterization of adult patients with type I Gaucher disease and carrier frequency analysis of Leu444Pro - a common Gaucher disease mutation in India.
Sheth J; Pancholi D; Mistri M; Nath P; Ankleshwaria C; Bhavsar R; Puri R; Phadke S; Sheth F
BMC Med Genet; 2018 Oct; 19(1):178. PubMed ID: 30285649
[TBL] [Abstract][Full Text] [Related]
16. Properties of beta-glucosidase in cultured skin fibroblasts from controls and patients with Gaucher disease.
Turner BM; Hirschhorn K
Am J Hum Genet; 1978 Jul; 30(4):346-58. PubMed ID: 102189
[TBL] [Abstract][Full Text] [Related]
17. Gaucher disease. III. Substrate specificity of glucocerebrosidase and the use of nonlabeled natural substrates for the investigation of patients.
Choy FY; Davidson RG
Am J Hum Genet; 1980 Sep; 32(5):670-80. PubMed ID: 6775530
[TBL] [Abstract][Full Text] [Related]
18. Identification and expression of acid beta-glucosidase mutations causing severe type 1 and neurologic type 2 Gaucher disease in non-Jewish patients.
Grace ME; Desnick RJ; Pastores GM
J Clin Invest; 1997 May; 99(10):2530-7. PubMed ID: 9153297
[TBL] [Abstract][Full Text] [Related]
19. Glucosylceramide accumulation is not confined to the lysosome in fibroblasts from patients with Gaucher disease.
Fuller M; Rozaklis T; Lovejoy M; Zarrinkalam K; Hopwood JJ; Meikle PJ
Mol Genet Metab; 2008 Apr; 93(4):437-43. PubMed ID: 18162427
[TBL] [Abstract][Full Text] [Related]
20. Evidence for the deficiency of beta-glucosidase-activating factor in fibroblasts of patients with I-cell disease.
Varon R; Kleijer WJ; Thompson EJ; d'Azzo A
Hum Genet; 1982; 62(1):66-9. PubMed ID: 6818133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
